Authors
Loading...
Novel GenoPrime-Perturb-seq technology assesses individual GATA2 variants in hematopoietic stem cells, indicating its potential to clarify variant pathogenicity.
Semba et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: